Search Results - "Trehu, Elizabeth G"

Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia by Attar, Eyal C, De Angelo, Daniel J, Supko, Jeffrey G, D'Amato, Ferdinando, Zahrieh, David, Sirulnik, Andres, Wadleigh, Martha, Ballen, Karen K, McAfee, Steve, Miller, Kenneth B, Levine, James, Galinsky, Ilene, Trehu, Elizabeth G, Schenkein, David, Neuberg, Donna, Stone, Richard M, Amrein, Philip C

“…Purpose: Proteasome inhibition results in cytotoxicity to the leukemia stem cell in vitro . We conducted this phase I study to determine if the proteasome…”
Get full text

Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy by van den Blink, Bernt, Dillingh, Marlous R, Ginns, Leo C, Morrison, Lake D, Moerland, Matthijs, Wijsenbeek, Marlies, Trehu, Elizabeth G, Bartholmai, Brian J, Burggraaf, Jacobus

“…Abnormal fibrogenic repair response upon alveolar injury is believed to play an important role in the pathogenesis of idiopathic pulmonary fibrosis (IPF)…”
Get full text

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies by Orlowski, Robert Z., Voorhees, Peter M., Garcia, Reynaldo A., Hall, Melissa D., Kudrik, Fred J., Allred, Tammy, Johri, Anandhi R., Jones, Paul E., Ivanova, Anastasia, Van Deventer, Hendrik W., Gabriel, Don A., Shea, Thomas C., Mitchell, Beverly S., Adams, Julian, Esseltine, Dixie-Lee, Trehu, Elizabeth G., Green, Marie, Lehman, Mary Jo, Natoli, Susan, Collins, Jason M., Lindley, Celeste M., Dees, E.Claire

“…Proteasome inhibitors, a novel class of chemotherapeutic agents, enhance the antitumor efficacy of anthracyclines in vitro and in vivo. We therefore sought to…”
Get full text

Hillmen trial of alemtuzumab in first-line chronic lymphocytic leukemia still provides valuable information by Sirard, Cynthia, Trehu, Elizabeth G

Get full text

Phase 1, first-in-human trial of JTX-8064, an anti-LILRB2/ILT4 monoclonal antibody, as monotherapy and in combination with anti-PD-1 in adult patients with advanced solid tumors (INNATE) by Papadopoulos, Kyriakos P., Lakhani, Nehal J., Yap, Timothy A., Naumovski, Allison L, Brown, Karen S, Umiker, Ben, McGrath, Lara, Zhang, Weidong, Stack, Edward, Riley, Gosia, Mota, Nancy, Tasillo, Christina, Laken, Haley, Trehu, Elizabeth G., Baeck, Johan

“…Abstract only TPS2672 Background: Leukocyte Immunoglobulin-like receptor B2 [LILRB2; immunoglobulin-like transcript 4 (ILT4)] is an immunoinhibitory protein…”
Get full text

Biomarker-driven indication selection in JTX-2011 ICONIC clinical trial by Hirsch, Heather Anne, Reeves, Jason, Zi, Tong, Deshpande, Amit, Yang, Guang, Needham, Alexander, Shu, Jenny, Khattri, Arun, Brisson, Ryan J., Tan, Carol, Harvey, Christopher, Law, Deborah, Michaelson, Jennifer, Trehu, Elizabeth G., Sathyanarayanan, Sriram, Seiwert, Tanguy Y.

“…Abstract only 11602 Background: ICOS (Inducible T cell CO-Stimulator) is a co-stimulatory molecule expressed primarily on T lymphocytes. Clinical and…”
Get full text

Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors; predicted vs observed pharmacokinetics (PK) in ICONIC by Burris, Howard A., Callahan, Margaret K., Tolcher, Anthony W., Kummar, Shivaani, Falchook, Gerald Steven, Pachynski, Russell Kent, Tykodi, Scott S., Gibney, Geoffrey Thomas, Seiwert, Tanguy Y., Gainor, Justin F., LoRusso, Patricia, Hilbert, James, Apgar, Josh F, Hua, Fei, Burke, John M, Lazaro, Manny, Clancy, Myles, Ding, Baoyu, Trehu, Elizabeth G., Yap, Timothy Anthony

“…Abstract only 3033 Background: JTX-2011 is an agonist monoclonal antibody that targets ICOS, Inducible CO-Stimulator of T cells. A dual mechanism of action is…”
Get full text

Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1 results by Verstovsek, Srdan, Mesa, Ruben A., Foltz, Lynda M., Gupta, Vikas, Mascarenhas, John, Ritchie, Ellen K., Hoffman, Ronald, Silver, Richard T., Hong, Wan-Jen, Kremyanskaya, Marina, Trehu, Elizabeth G., Kantarjian, Hagop M., Gotlib, Jason R.

“…Abstract only…”
Get full text

A phase Ib trial of FOLFIRINOX plus saridegib, an oral hedgehog (Hh) inhibitor, in pts with advanced pancreatic cancer (PDAC) by Ko, Andrew H., LoConte, Noelle K., Kantoff, Emily, Ross, Robert W., Trehu, Elizabeth G., Tempero, Margaret A., Kelley, Robin Katie, Venook, Alan Paul, Wu, Timothy, Kindler, Hedy Lee

“…Abstract only 3105 Background: FOLFIRINOX has emerged as the optimal 1 st -line treatment option for pts with advanced PDAC and good performance status;…”
Get full text

Phase I Dose Escalating Trial of Bortezomib (Velcade®) in Combination with Idarubicin and Cytarabine in Patients with Acute Myeloid Leukemia by Attar, Eyal C., DeAngelo, Daniel J., Ballen, Karen K., Learner, Emily, Trehu, Elizabeth G., Schenkein, David P., Levine, James D., Stone, Richard M., Amrein, Philip C.

“…Conventional therapy for acute myeloid leukemia (AML) consists of a combination of cytarabine and an anthracycline such as idarubicin. Currently, most patients…”
Get full text

A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor by MCDERMOTT, D. F, TREHU, E. G, MIER, J. W, SORCE, D, RAND, W, RONAYNE, L, KAPPLER, K, CLANCY, M, KLEMPNER, M, ATKINS, M. B

“…Our purpose was to determine the maximum tolerated dose and toxicity associated with soluble Chinese hamster ovary [s(CHO)] recombinant human interleukin (IL)…”
Get full text

Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera by TREHU, E. G, MIER, J. W, ATKINS, M. B, DUBOIS, J. S, SORCE, D, KLEMPNER, M. S, EPSTEIN, M, DINARELLO, C. A, SHAPIRO, L, KAPPLER, K, RONAYNE, L

“…Our purpose was to determine the effective biological dose and/or maximum tolerated dose of recombinant human tumor necrosis factor receptor:IgG chimera…”
Get full text

A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma by Weiss, G R, Margolin, K A, Sznol, M, Atkins, M B, Oleksowicz, L, Isaacs, R, Sosman, J A, Doroshow, J H, Trehu, E G, Dutcher, J P

Get more information

Possible myocardial toxicity associated with interleukin-4 therapy by Trehu, E G, Isner, J M, Mier, J W, Karp, D D, Atkins, M B

“…Interleukin (IL)-4 is a cytokine produced by T lymphocytes, which may play a role in allergic inflammatory processes through its stimulatory effects on…”
Get more information

Cost of screening for colorectal cancer: results of a community mass screening program and review of the literature by Trehu, E G, Cooper, J N

“…Colorectal cancer is the second most common form of cancer in the United States, but controversy exists over the feasibility, benefits, and methods of…”
Get more information

Suppression of IL-2-induced SAA gene expression in mice by the administration of an IL-1 receptor antagonist by Numerof, R P, Sipe, J D, Trehu, E G, Dinarello, C A, Mier, J W

“…The hepatic acute phase response induced by the administration of interleukin (IL)-2 is most likely mediated by secondary cytokines. In this investigation, we…”
Get more information

Book reviews -- Gastrointestinal Oncology edited by James D. Ahlgren and John S. MacDonald by Trehu, Elizabeth G

“…The number of pages allotted to each cancer is generally an appropriate reflection of the disease's prevalence and the range of therapeutic options, with…”
Get full text

Book Review by Trehu, Elizabeth G

Get full text

Book Review Gastrointestinal Oncology Edited by James D. Ahlgren and John S. MacDonald. 659 pp., illustrated. Philadelphia, J.B. Lippincott, 1992. $95. 0-397-51150-7 by Trehu, Elizabeth G.

Get full text

Book Review by Trehu, Elizabeth G

“…The integration of medical, surgical, and radiation oncology is central to the management of gastrointestinal solid tumors. This combined-treatment approach is…”
Get full text